Profound Medical Showcases AI-Powered TULSA Procedure at SRS2026
Event summary
- Profound Medical's TULSA Procedure will be featured in multiple presentations at the SRS2026 conference, including real-world outcomes and randomized controlled trials.
- The Society of Incisionless Surgery (SIS) will spotlight Profound as one of eight companies shaping the future of surgery during its plenary session.
- Profound's management team will participate in an investor session on July 22, 2026, moderated by analysts from Stifel Financial and Wells Fargo.
The big picture
Profound Medical's strong presence at SRS2026 underscores the growing importance of AI and robotics in minimally invasive prostate cancer treatments. The company's TULSA Procedure is positioned as a key player in the shift towards personalized, incisionless surgical solutions. With increasing regulatory support and clinical validation, Profound is well-positioned to capitalize on the expanding market for advanced robotic-assisted therapies.
What we're watching
- Adoption Pace
- How the TULSA Procedure's AI-driven learning curve will affect its adoption rate among surgeons.
- Regulatory Impact
- Whether the recent CPT Category 1 codes for the TULSA Procedure will drive broader reimbursement and usage.
- Competitive Positioning
- The pace at which Profound can differentiate itself in the growing market for incisionless robotic surgery solutions.